Integrating biology into clinical trial design

Area of Science:

• Critical care medicine
• Translational research
• Clinical trial design

Background:

• Critical care medicine faces challenges with syndromes like ARDS, sepsis, and AKI due to patient heterogeneity.
• Few interventions show broad effectiveness in large trials, highlighting the need for personalized approaches.

Approach:

• Integrate biological considerations into clinical trial design to address patient heterogeneity.
• Utilize predictive enrichment for patient selection.
• Incorporate time-dependent assessments and biological markers as surrogate outcomes.

Key Points:

• Biological assessment can identify homogeneous subgroups within critical care syndromes.
• Differential treatment effects exist across these subgroups.
• Personalized treatment strategies are achievable through tailored trial designs.

Conclusions:

• Integrating biological heterogeneity into clinical trial design is crucial for advancing critical care.
• Modified trial designs can improve the detection of beneficial targeted therapies.
• This strategy enables testing multiple treatments per patient, optimizing personalized medicine.